Herantis Pharma Plc, Press Release, 30 September 2021 at 12:00 EEST
Herantis Pharma Plc (“Herantis”), focusing on disease-modifying therapies for debilitating neurodegenerative diseases, today announced that a review describing genetically targeted clinical trials in Parkinson’s disease has been published in Genes, a peer-reviewed open access journal of genetics and genomics. Precision medicine and focus on genetically defined subtypes of disease have been successful in oncology clinical trials in the past decade and similar approaches implementing genetics, biomarkers and smart clinical trial designs are now considered a key for successful clinical trials in Parkinson’s disease.
The review titled, “Genetically Targeted Clinical Trials in Parkinson’s Disease: Learning from the Successes Made in Oncology” by Magnus Sjögren, Henri J. Huttunen, Per Svenningsson and Håkan Widner was published on September 28, 2021.
“It is critically important that we now start to build similar biomarker-driven approaches in Parkinson’s disease,” comments said Dr. Henri Huttunen, Co-Founder & Chief Scientific Officer of Herantis. “In our recent CDNF Phase I clinical study, we took the first steps in this direction, and identified several potential biomarker candidates for further development. We are now building on this foundation.”
The review can be found on our website via the following link: Herantis Public Materials; or by accessing Genes via tha following link: Genes Journal.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. CDNF (a biological protein) is Herantis’ lead program and a clinical stage asset; and xCDNF (HER-096) (a synthetic peptide version of CDNF) is Herantis’ follow-on program. CDNF is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. Both CDNF and xCDNF (HER-096), via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other neurodegenerative diseases with a significant therapeutic impact on the quality of patients’ lives.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com